A012103_OPTIMICE-PCR

Submitted by rfreitag on

Short Title: OPTIMICE-PCR

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Study Number:

A012103

Study Status:

Enrolling

Treatment Agent:

Pembrolizumab

Resources and Links

National Clinical Trial Identified Number: NCT05812807

Disease:

  • Breast Cancer

Study Phase:

III

researchcancer@cooperhealth.edu

Article Title

De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Hide from Search:

Off

Physician Name:

Department:

ARTEMIDE 03

Submitted by rfreitag on

Short Title: ARTEMIDE 03

The purpose of this study is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a 1L treatment for patients with non-squamous mNSCLC whose tumors express PD-L1 (TC ≥ 1%).

Study Number:

ARTEMIDE 03/D702FC00001

Study Status:

Enrolling

Treatment Agent:

Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed

Resources and Links

National Clinical Trial Identified Number: NCT06627647

Disease:

  • Non-Small Cell Lung Cancer

Study Phase:

III

researchcancer@cooperhealth.edu

Article Title

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

Hide from Search:

Off

Physician Name:

Department:

ARTEMIDE-02

Submitted by rfreitag on

Short Title: ARTEMIDE-02

The purpose of the study is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line (1L) treatment for patients with squamous metastatic non-small cell lung cancer (mNSCLC) whose tumors express PD-L1 (tumor cells (TC) ≥ 1%).

Study Number:

ARTEMIDE-02/D702BC00001

Study Status:

Enrolling

Treatment Agent:

Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel

Resources and Links

National Clinical Trial Identified Number: NCT06692738

Disease:

  • Non-Small Lung Disease

Study Phase:

III

researchcancer@cooperhealth.edu

Article Title

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

Hide from Search:

Off

Physician Name:

Department:

4.81 out of 5 (140 ratings, 40 reviews)
4.87 out of 5 (165 ratings, 38 reviews)
4.87 out of 5 (203 ratings, 68 reviews)
4.95 out of 5 (363 ratings, 119 reviews)
4.82 out of 5 (126 ratings, 46 reviews)
4.89 out of 5 (144 ratings, 46 reviews)
Subscribe to